alpha-MSH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-10 and is reviewed periodically as new material appears.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
At the end of the month, it opened a unit in Seoul (owned by 2F Enterprises) and one in Brunei (owned by a subfranchise of A&W Singapore). As of June 1998, A&W only had two restaurants in Mexico. The Cairo branch opened on August 1, 1998, under local franchise American Egyptian Foreign Investments, with Egypt becoming the seventeenth country outside of the United States to open a location. The first co-branded A&W restaurant, tied with Mexican food chain Amigos, opened in Lincoln in 1997. There were plans to increase the amount of co-branded locations across Nebraska by four in the second half of 1998. The goal of the co-branded restaurant was to allure more customers who did not prefer Mexican food. On March 16, 1999, it announced the opening of a restaurant in Dhaka with franchisee Global Supplies Limited due in September that year, with four more planned. The restaurant in Lodi took part in a world record for the largest root beer float of 2562.5 gallons on June 19, 1999, the eve of the eightieth anniversary of the chain. That same year, the chain attempted to enter the Korean market by finding local partners, aiming to grow in the Korean market in the first half of 2000. The plan was ultimately shelved. A&W merged with Long John Silver's to form Yorkshire Global Restaurants based in Lexington, Kentucky in March 1999. Kevin Bazner was promoted president of the chain in July. In 2000, Yorkshire agreed to test multi-branded locations with Tricon Global Restaurants. A grocery location opened in February that year in Idaho.
Changes to the curriculum of American history during the 2010s, especially in left-leaning states, have led to large numbers young Americans having a low opinion of their country and their historical figures. On the other hand, the decline of belief in American exceptionalism is a long-term trend, not unique to this cohort.
In Germany, rhinoplastic technique was refined by surgeons such as the Berlin University professor of surgery Karl Ferdinand von Gräfe (1787–1840), who published Rhinoplastik (Rebuilding the Nose, 1818) wherein he described 55 historical plastic surgery procedures, and his technically innovative free-graft nasal reconstruction (with a tissue-flap harvested from the patient's arm), and surgical approaches to eyelid, cleft lip, and cleft palate corrections. Dr. von Gräfe's protégé, the medical and surgical polymath Johann Friedrich Dieffenbach (1794–1847), who was among the first surgeons to anaesthetize the patient before performing the nose surgery, published Die Operative Chirurgie (Operative Surgery, 1845), which became a foundational medical and plastic surgical text (see strabismus, torticollis). Moreover, the Prussian Jacques Joseph (1865–1934) published Nasenplastik und sonstige Gesichtsplastik (Rhinoplasty and other Facial Plastic Surgeries, 1928), which described refined surgical techniques for performing nose-reduction rhinoplasty via internal incisions. In the United States, in 1887, the otolaryngologist John Orlando Roe (1848–1915) performed the first modern endonasal rhinoplasty (closed rhinoplasty) in order to treat saddle nose deformities. In America June 1894, a successful operation was reported to remove cartilage and "gratify the vanity" of a large nosed individual.
In enzymology, cholestenone 5alpha-reductase (EC 1.3.1.22) is an enzyme that catalyzes several chemical reactions of steroids in which a cholest-4-en-3-one is converted to the corresponding 5α-dihydrocholestan-3-one. For example, 5α-dihydroprogesterone is the product of the reduction of progesterone:
After protein staining and documentation of the banding pattern, the polyacrylamide gel can be dried for archival storage. Proteins can be extracted from it at a later date. The gel is either placed in a drying frame (with or without the use of heat) or in a vacuum dryer. The drying frame consists of two parts, one of which serves as a base for a wet cellophane film to which the gel and a one percent glycerol solution are added. Then a second wet cellophane film is applied bubble-free, the second frame part is put on top and the frame is sealed with clips. The removal of the air bubbles avoids a fragmentation of the gel during drying. The water evaporates through the cellophane film. In contrast to the drying frame, a vacuum dryer generates a vacuum and heats the gel to about 50 °C.
Sources: en.wikipedia.org
Transcranial direct current stimulation (tDCS) Transcutaneous electrical nerve stimulation (TENS) and a prescription variant of TENS, transcutaneous afferent patterned stimulation (TAPS) Electroconvulsive therapy (ECT)
The Socialist Party of Albania emerged in the aftermath of the fall of communism in Albania that had dominated Albanian politics since the end of World War II. The dissolution of the People's Socialist Republic prompted a reevaluation of political ideologies and a quest for democratic governance, paving the way for the rise of multiple political entities. The roots of the Socialist Party can be traced back to the Party of Labour of Albania under its founder Enver Hoxha, which had been the ruling party for over four decades. Hoxha's successor Ramiz Alia was forced to introduce limited reforms in the late 1980s. On 11 December 1990, Alia announced that the PPSh had given up its monopoly of power. The PPSh won the 1991 Albanian Constitutional Assembly election, the first free elections held in the country in almost 80 years. By this time, it was no longer a Marxist–Leninist party. At an extraordinary congress on 10–13 June 1991, the PPSh reorganized as the PS in an effort to adapt to survive in the new system. Fatos Nano, a man from the intelligentsia, was elected the new chairman. Nano helped to reform the old Communist party and made it a member of the Socialist International. A faction of the party, led by Ilir Meta, split away from the PS in 2004 and formed the Socialist Movement for Integration (Lëvizja Socialiste për Integrim, LSI). On 10 October 2005, Nano resigned as the chairman of the PS after losing the 2005 Albanian parliamentary election, and was succeeded by Edi Rama.
Alpha: Lineage B.1.1.7 emerged in the United Kingdom in September 2020, with evidence of increased transmissibility and virulence. Notable mutations include N501Y and P681H. An E484K mutation in some lineage B.1.1.7 virions has been noted and is also tracked by various public health agencies. Beta: Lineage B.1.351 emerged in South Africa in May 2020, with evidence of increased transmissibility and changes to antigenicity, with some public health officials raising alarms about its impact on the efficacy of some vaccines. Notable mutations include K417N, E484K and N501Y. Gamma: Lineage P.1 emerged in Brazil in November 2020, also with evidence of increased transmissibility and virulence, alongside changes to antigenicity. Similar concerns about vaccine efficacy have been raised. Notable mutations also include K417N, E484K and N501Y. Delta: Lineage B.1.617.2 emerged in India in October 2020. There is also evidence of increased transmissibility and virulence, and changes to antigenicity. Omicron: Lineage B.1.1.529 emerged around Botswana in November 2021. This lineage demonstrated significantly increased transmissibility and changes to antigenicity, and it subsequently dominated all circulating versions of the virus ever since its emergence. Omicron variant BA.3.2 was reported to be widespread across Europe and the US in April 2026. The variant has many changes to the spike protein, but had not been found to be more virulent than other Omicron variants, and existing vaccines protected against it.
== Challenges == According to James Bray, three of the challenges facing a stepfamily are financial and living arrangements, resolving feelings about the previous marriage, and anticipating parenting changes. Research has shown that parents who are constantly fighting with their ex-spouse tend to make their children suffer mentally and emotionally. However, parents who are close with their ex-spouse tend to make their new spouse insecure and anxious. Additional challenges that a step- or blended family face are those regarding the inherent bond that biological parents have with their children and vice versa. Stepparents often face significant difficulties when interacting with the biological parent of their gender. Often, biological parents feel as though the stepfather or stepmother will ultimately replace them in the mind(s) of the child(ren). This is a common feeling for a parent when faced with the new circumstance of blended families.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.